BioNexus Gene Lab (BGLC)
Market Price (6/20/2026): $2.58 | Market Cap: $6.2 MilSector: Materials | Industry: Specialty Chemicals
BioNexus Gene Lab (BGLC)
Market Price (6/20/2026): $2.58Market Cap: $6.2 MilSector: MaterialsIndustry: Specialty Chemicals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -59% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -164% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -43%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -99% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% High stock price volatilityVol 12M is 291% Key risksBGLC key risks include [1] significant financial instability and a history of Nasdaq delisting risk, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -59% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -164% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -43%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -99% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% |
| High stock price volatilityVol 12M is 291% |
| Key risksBGLC key risks include [1] significant financial instability and a history of Nasdaq delisting risk, Show more. |
Qualitative Assessment
AI Analysis | Feedback
BioNexus Gene Lab (BGLC) stock has lost about 5% since 2/28/2026 because of the following key factors:
1. Significant Revenue Decline in Fiscal Q1 2026. BioNexus Gene Lab Corp (BGLC) reported a substantial decrease in revenue for its fiscal Q1 2026 (ended March 31, 2026), with revenue falling approximately 99% year-over-year to $22.84K. The company also reported an Earnings Per Share (EPS) of -$0.23 for the quarter.
2. Business Strategy Shift and Repositioning of Chemrex. The company is undergoing a strategic pivot, transitioning its Chemrex subsidiary from chemical trading, which experienced a major decline in volume, toward Contract Development and Manufacturing Organization (CDMO) services and the commercial rollout of its VitaGuard™ MRD platform. This significant business repositioning, while aiming for long-term growth, contributed to the short-term revenue reduction and likely introduced investor uncertainty during the transition period.
Show more
BioNexus Gene Lab (BGLC) stock has lost about 5% since 2/28/2026 because of the following key factors:
1. Significant Revenue Decline in Fiscal Q1 2026. BioNexus Gene Lab Corp (BGLC) reported a substantial decrease in revenue for its fiscal Q1 2026 (ended March 31, 2026), with revenue falling approximately 99% year-over-year to $22.84K. The company also reported an Earnings Per Share (EPS) of -$0.23 for the quarter.
2. Business Strategy Shift and Repositioning of Chemrex. The company is undergoing a strategic pivot, transitioning its Chemrex subsidiary from chemical trading, which experienced a major decline in volume, toward Contract Development and Manufacturing Organization (CDMO) services and the commercial rollout of its VitaGuard™ MRD platform. This significant business repositioning, while aiming for long-term growth, contributed to the short-term revenue reduction and likely introduced investor uncertainty during the transition period.
3. Delayed Filing of Annual 10-K Report. On March 31, 2026, BioNexus Gene Lab Corp announced its inability to file its annual 10-K report by the Securities and Exchange Commission (SEC) deadline. Such delays often signal potential issues with financial reporting, compliance, or internal controls, which can negatively impact investor confidence.
Show less
Stock Movement Drivers
Fundamental Drivers
The -4.2% change in BGLC stock from 2/28/2026 to 6/19/2026 was primarily driven by a -43.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.72 | 2.61 | -4.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 5 | -43.9% |
| P/S Multiple | 0.5 | 1.2 | 129.8% |
| Shares Outstanding (Mil) | 2 | 2 | -25.7% |
| Cumulative Contribution | -4.2% |
Market Drivers
2/28/2026 to 6/19/2026| Return | Correlation | |
|---|---|---|
| BGLC | -4.2% | |
| Market (SPY) | 9.2% | 27.7% |
| Sector (XLB) | -2.6% | 24.9% |
Fundamental Drivers
The -42.5% change in BGLC stock from 11/30/2025 to 6/19/2026 was primarily driven by a -43.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.54 | 2.61 | -42.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 5 | -43.9% |
| P/S Multiple | 0.9 | 1.2 | 37.9% |
| Shares Outstanding (Mil) | 2 | 2 | -25.7% |
| Cumulative Contribution | -42.5% |
Market Drivers
11/30/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| BGLC | -42.5% | |
| Market (SPY) | 9.9% | 27.9% |
| Sector (XLB) | 17.0% | 13.9% |
Fundamental Drivers
The -39.2% change in BGLC stock from 5/31/2025 to 6/19/2026 was primarily driven by a -42.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.29 | 2.61 | -39.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 5 | -42.7% |
| P/S Multiple | 0.8 | 1.2 | 42.8% |
| Shares Outstanding (Mil) | 2 | 2 | -25.7% |
| Cumulative Contribution | -39.2% |
Market Drivers
5/31/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| BGLC | -39.2% | |
| Market (SPY) | 28.1% | 5.7% |
| Sector (XLB) | 22.4% | 13.6% |
Fundamental Drivers
The -92.4% change in BGLC stock from 5/31/2023 to 6/19/2026 was primarily driven by a -75.6% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 34.52 | 2.61 | -92.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 5 | -48.3% |
| P/S Multiple | 4.9 | 1.2 | -75.6% |
| Shares Outstanding (Mil) | 1 | 2 | -40.1% |
| Cumulative Contribution | -92.4% |
Market Drivers
5/31/2023 to 6/19/2026| Return | Correlation | |
|---|---|---|
| BGLC | -92.4% | |
| Market (SPY) | 85.7% | -1.1% |
| Sector (XLB) | 46.5% | -4.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BGLC Return | -7% | -55% | -95% | -47% | 41% | -36% | -99% |
| Peers Return | -16% | -58% | 23% | 42% | 51% | 11% | 3% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| BGLC Win Rate | 33% | 25% | 25% | 50% | 33% | 50% | |
| Peers Win Rate | 52% | 27% | 50% | 52% | 52% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BGLC Max Drawdown | -58% | -68% | -98% | -85% | -95% | -52% | |
| Peers Max Drawdown | -45% | -70% | -44% | -30% | -46% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GH, NTRA, ILMN, VCYT, NEO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | BGLC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -93.3% | -18.8% |
| % Gain to Breakeven | 1397.4% | 23.1% |
| Time to Breakeven | 53 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.6% | -7.8% |
| % Gain to Breakeven | 15.7% | 8.5% |
| Time to Breakeven | 319 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -81.1% | -6.7% |
| % Gain to Breakeven | 429.6% | 7.1% |
| Time to Breakeven | 41 days | 31 days |
In The Past
BioNexus Gene Lab's stock fell -93.3% during the 2025 US Tariff Shock. Such a loss loss requires a 1397.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BGLC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -93.3% | -18.8% |
| % Gain to Breakeven | 1397.4% | 23.1% |
| Time to Breakeven | 53 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -81.1% | -6.7% |
| % Gain to Breakeven | 429.6% | 7.1% |
| Time to Breakeven | 41 days | 31 days |
In The Past
BioNexus Gene Lab's stock fell -93.3% during the 2025 US Tariff Shock. Such a loss loss requires a 1397.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BioNexus Gene Lab (BGLC)
BioNexus Gene Lab Corp. (BGLC) is a healthcare diagnostics company primarily operating in Malaysia, specializing in providing a broad range of medical laboratory services. The company offers a comprehensive portfolio of diagnostic tests and health screening programs aimed at early detection, diagnosis, and monitoring of various health conditions.
Its core services include an extensive array of diagnostic tests covering areas such as general blood and urine analysis, genetic testing, cancer markers, infectious diseases, allergies, and toxicology. BioNexus Gene Lab also provides health screening packages for individuals and corporations, alongside advanced solutions like its Laboratory Information Management System (LIMS) and Point-of-Care Testing (POCT) devices, which enhance efficiency and accessibility of diagnostic services. During the recent global health crisis, the company was also a significant provider of COVID-19 testing services.
BioNexus Gene Lab primarily serves a diverse clientele including hospitals, clinics, and medical professionals seeking reliable diagnostic support. Additionally, it caters to corporations for employee wellness and health screening initiatives, and directly to individuals through various channels. Its market focus is predominantly within Malaysia, with ambitions for regional expansion across Southeast Asia, positioning itself as a crucial partner in preventive and diagnostic healthcare.
```AI Analysis | Feedback
AI Analysis | Feedback
- COVID-19 RT-PCR Tests: Provides highly accurate molecular diagnostic tests for the detection of SARS-CoV-2, a significant service offered during the pandemic.
- Genetic Testing Services: Offers a range of DNA tests to provide insights into genetic predispositions, health risks, and other personalized genetic information.
- Molecular Diagnostic Lab Services: Operates a diagnostic laboratory providing advanced molecular testing capabilities for various diseases and conditions beyond just COVID-19.
AI Analysis | Feedback
BioNexus Gene Lab (BGLC) primarily provides genetic testing and molecular diagnostic services. While many of their services are ultimately for individual patients, these are often facilitated and ordered by healthcare providers or institutions. Given the nature of their services, their customer base can be broadly categorized as follows:
-
Healthcare Providers & Institutions: This major customer category includes hospitals, clinics, and independent medical practitioners who utilize BioNexus Gene Lab's diagnostic and genetic testing services for their patients. These entities serve as the direct ordering and often billing customers for a wide range of molecular diagnostics, including infectious disease testing, genetic screening, and cancer risk assessments.
-
Individual Patients: These are the ultimate recipients of BioNexus Gene Lab's genetic testing and diagnostic services. Patients are often referred by their healthcare providers to gain personalized insights into health risks, inherited conditions, pharmacogenomic responses, or general wellness and ancestry information.
-
Research & Corporate Clients: This category encompasses pharmaceutical companies, biotechnology firms, academic research institutions, and other corporate entities. These clients may engage BioNexus Gene Lab for specialized R&D support, clinical trial services, or large-scale health screening programs (e.g., employee testing for infectious diseases).
AI Analysis | Feedback
AI Analysis | Feedback
Lee Su-Leng Tan, President, Chief Executive Officer, Secretary, Director, and Principal Accounting Officer
Mr. Lee Su-Leng Tan was appointed Chief Executive Officer and Director of BioNexus Gene Lab Corp. on December 11, 2023. He previously served as the company's Acting Chief Financial Officer. His compensation has increased while BioNexus Gene Lab Corp. remains unprofitable. He has publicly stated that Chemrex, a wholly-owned subsidiary, represents a strategic platform within the company's broader technology ecosystem.
Angeline Chong (Chong Set Fui), Chief Financial Officer and Principal Financial Officer
Ms. Angeline Chong was appointed Chief Financial Officer and Principal Financial Officer of BioNexus Gene Lab Corp., effective June 17, 2025. She also serves as a Director of Chemrex, a wholly-owned subsidiary. Ms. Chong, 62, brings over 25 years of senior financial leadership experience, including her previous role as Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She holds ACCA and MIA certifications.
Matthew L. Barsing, Chairman of Chemrex Corporation Sdn. Bhd.
Mr. Matthew L. Barsing was appointed Chairman of Chemrex Corporation Sdn. Bhd., a wholly-owned subsidiary of BioNexus Gene Lab Corp., on February 23, 2026. He is described as a governance-focused board advisor and economic strategist with over 25 years of experience working with governments, institutional stakeholders, and companies across ASEAN, Australia, and emerging markets. Mr. Barsing previously served as Head of Foreign Direct Investment at Malaysia's Multimedia Development Corporation (MDeC). Currently, he serves as a Director and Board Member of EPS Consultants and is a Mentor at Orbit Startups. He has also contributed to Malaysian national AI-related working group initiatives.
AI Analysis | Feedback
The key risks to BioNexus Gene Lab (symbol: BGLC) are:
- Financial Instability and Delisting Risk: BioNexus Gene Lab Corp. faces a significant risk of delisting from Nasdaq due to persistent ongoing losses, despite revenue streams from its subsidiary, Chemrex Corporation. The company is considered a "penny stock," which typically experiences high volatility and stability issues, and has been evaluated negatively with "several negative signals" and a "falling trend." Additionally, there is a "moderate risk of bankruptcy."
- Competitive Landscape and Innovation: BioNexus Gene Lab operates within a highly competitive biotechnology market, where it competes with other firms specializing in genetic testing. The company's continued success is contingent on its ability to innovate and introduce new products, necessitating continuous investment in research and development to maintain a competitive edge and meet evolving market demands.
- Regulatory Hurdles: Navigating the complex regulatory environment poses a continuous challenge for biotechnology companies like BioNexus Gene Lab. Changes in regulations can significantly impact the company's operations, introduce delays in product development and commercialization, and potentially hinder its growth trajectory.
AI Analysis | Feedback
AI Analysis | Feedback
BioNexus Gene Lab (BGLC) operates in two primary markets: the trading of industrial chemicals and the provision of genomic screening services.
Industrial Chemicals Market
The addressable market for BioNexus Gene Lab's trading of industrial chemical raw materials is Southeast Asia. This market was valued at approximately $46.86 billion in 2024 and is projected to reach around $84.24 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 6.04%. This growth is driven by increasing demand across industries such as textiles, construction, automotive, and electronics in countries including Malaysia, Indonesia, and Vietnam.
Genomic Screening Services Market
BioNexus Gene Lab's genomic screening services, which include non-invasive blood-based genomic screening for early detection of diseases, operate within the broader liquid biopsy and precision genomic testing markets. The Asia Pacific Genomics Market, a key region for BGLC's diagnostic services, was estimated at USD 7.26 billion in 2024 and is projected to reach approximately USD 44.55 billion by 2035, growing at a CAGR of around 17.93% from 2025 to 2035. This growth is fueled by technological advancements in genome sequencing and increasing demand for healthcare testing.
AI Analysis | Feedback
1. Commercialization and Deployment of the VitaGuard™ MRD Platform in Southeast Asia: BioNexus Gene Lab has secured exclusive, perpetual rights to manufacture, market, and distribute the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across all ASEAN markets. The company has formally commenced its 2026 Deployment Phase for the VitaGuard™ platform, anticipating initial deployments in select Southeast Asian medical hubs during 2026. This advanced AI-enabled diagnostic tool for early cancer recurrence detection represents a significant new product launch and market expansion within its precision diagnostics segment.
2. Expansion into Contract Development and Manufacturing Organization (CDMO) Services and Biologics Production: BioNexus Gene Lab is strategically expanding its operations to include contract development and manufacturing organization (CDMO) services. The company plans to participate in biologics production, assay manufacturing, and diagnostic supply chains, backed by investments in quality systems, manufacturing capacity, and technical capabilities aligned with global CDMO standards. This diversification into new service offerings is expected to contribute to future revenue growth.
3. Strategic Partnership and Commercialization of BirchBioMed's FS2 Topical Platform in Southeast Asia: BioNexus Gene Lab has entered into a non-binding strategic partnership term sheet with BirchBioMed Inc. to advance Birch's FS2 (kynurenic acid) topical platform in Southeast Asia. This partnership positions BGLC to provide market access, regulatory and clinical-trial strategy, and commercialization support in key markets like Malaysia and Singapore, thereby introducing a new product line and expanding its therapeutic offerings.
4. Strategic Evolution and Potential Expansion of the Specialty Chemical Raw Materials Distribution Business: BioNexus Gene Lab is undergoing a strategic evaluation of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., which focuses on the trading of industrial chemical raw materials. While a governance restructuring has been completed, the company continues to assess optimal strategic directions for Chemrex, which may involve biotechnology-focused development opportunities, advanced manufacturing, healthcare-related infrastructure, or other technology-aligned initiatives, suggesting potential for growth or a strategic pivot within this segment.
AI Analysis | Feedback
Share Issuance
- BioNexus Gene Lab Corp. closed an underwritten public offering on July 24, 2023, issuing 1,437,500 shares of common stock at $4.00 per share, resulting in gross proceeds of $5.75 million.
- On November 7, 2025, the company filed a registration statement on Form S-3 to register up to $100 million of securities for potential future offerings and launched an At-The-Market (ATM) program for up to $20 million of common stock.
- As part of a $500 million Equity Purchase Agreement with ARC Group International Ltd. on December 2, 2025, BioNexus Gene Lab Corp. issued 175,000 shares of common stock as a one-time fee, priced at $4.32 per share.
Inbound Investments
- BioNexus Gene Lab Corp. entered into a $500,000,000 Equity Purchase Agreement with ARC Group International Ltd. on December 2, 2025, providing discretionary access to capital over a 36-month commitment period to advance strategic initiatives.
- Institutional investors, including DRW Securities LLC and Virtu Financial LLC, collectively purchased 33,179 shares of BioNexus Gene Lab's stock, representing approximately $136.53K in transactions, within the 24 months leading up to March 2026.
Outbound Investments
- On November 12, 2025, BioNexus Gene Lab Corp. established a strategic alliance with Fidelion Diagnostics Pte. Ltd., which included taking a 15% equity stake in Fidelion.
Capital Expenditures
- BioNexus Gene Lab Corp. is undertaking capital allocation for the regional deployment of its VitaGuard™ Minimal Residual Disease (MRD) platform in Southeast Asia, with initial plans in January 2026 to integrate the platform into oncology workflows and support broader commercialization efforts.
- The company plans investments in quality systems, manufacturing capacity, and technical capabilities to expand into Contract Development and Manufacturing Organization (CDMO) services, biologics production, assay manufacturing, and diagnostic supply chains.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can BioNexus Gene Lab Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 92.70 |
| Mkt Cap | 10.8 |
| Rev LTM | 913 |
| Op Inc LTM | -41 |
| FCF LTM | 35 |
| FCF 3Y Avg | -8 |
| CFO LTM | 94 |
| CFO 3Y Avg | 40 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.9% |
| Rev Chg 3Y Avg | 16.2% |
| Rev Chg Q | 16.3% |
| QoQ Delta Rev Chg LTM | 3.7% |
| Op Inc Chg LTM | 0.9% |
| Op Inc Chg 3Y Avg | 10.0% |
| Op Mgn LTM | -11.7% |
| Op Mgn 3Y Avg | -15.9% |
| QoQ Delta Op Mgn LTM | 1.2% |
| CFO/Rev LTM | 5.7% |
| CFO/Rev 3Y Avg | 1.2% |
| FCF/Rev LTM | 1.1% |
| FCF/Rev 3Y Avg | -3.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Trading of industrial chemicals | 7 | 9 | |||
| Provision for genomic screening services | 0 | 0 | |||
| Investment Holding | 0 | 0 | |||
| Biochemical industry | 10 | 11 | 13 | ||
| Total | 7 | 10 | 10 | 11 | 13 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Provision for genomic screening services | -0 | -0 |
| Trading of industrial chemicals | -1 | -0 |
| Investment Holding | -2 | -1 |
| Total | -3 | -2 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Provision for genomic screening services | -0 | -0 |
| Trading of industrial chemicals | -1 | -0 |
| Investment Holding | -2 | -1 |
| Total | -3 | -2 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Trading of industrial chemicals | 5 | 7 | |
| Investment Holding | 2 | 1 | |
| Provision for genomic screening services | 2 | 3 | |
| Chemrex Corporation | 7 | ||
| MRNA Scientific | 5 | ||
| Total | 9 | 10 | 11 |
Price Behavior
| Market Price | $2.61 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/16/2020 | |
| Distance from 52W High | -76.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.18 | $3.50 |
| DMA Trend | down | down |
| Distance from DMA | 19.8% | -25.4% |
| 3M | 1YR | |
| Volatility | 66.0% | 293.1% |
| Downside Capture | 111.49 | -50.20 |
| Upside Capture | 81.78 | -49.58 |
| Correlation (SPY) | 30.9% | 5.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.91 | 0.06 | 0.30 | 0.92 | 0.92 | -0.67 |
| Up Beta | 0.60 | 0.40 | -1.25 | -0.20 | 1.05 | -0.48 |
| Down Beta | 1.87 | 1.30 | 1.68 | 2.26 | 7.55 | 5.22 |
| Up Capture | -32% | 11% | 10% | -5% | -39% | -7% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 16 | 24 | 47 | 94 | 293 |
| Down Capture | -490% | -130% | 110% | 172% | -28% | -705% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 22 | 36 | 71 | 143 | 432 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGLC | |
|---|---|---|---|---|
| BGLC | 5.7% | 292.7% | 0.71 | - |
| Sector ETF (XLB) | 21.2% | 17.5% | 0.94 | 13.3% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 5.1% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 0.6% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | 1.5% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 2.2% |
| Bitcoin (BTCUSD) | -40.0% | 42.5% | -1.08 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGLC | |
|---|---|---|---|---|
| BGLC | 140.2% | 683.1% | 1.04 | - |
| Sector ETF (XLB) | 5.9% | 19.0% | 0.20 | -3.2% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | -0.7% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | -5.8% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | -4.7% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | -6.2% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | -2.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGLC | |
|---|---|---|---|---|
| BGLC | 88.1% | 721.6% | 1.18 | - |
| Sector ETF (XLB) | 10.2% | 20.7% | 0.44 | -2.0% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | -1.9% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | -6.3% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | -3.4% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | -7.2% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | -2.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/14/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/18/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/15/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/16/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 08/16/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/14/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/18/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/15/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/16/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 08/16/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 04/06/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/18/2021 | 10-Q |
| 12/31/2020 | 03/30/2021 | 10-K |
| 09/30/2020 | 11/03/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/31/2020 | 10-K |
Industry Resources
| Materials Resources |
| Chemical & Engineering News (C&EN) |
| Mining.com |
| Plastics News |
| Specialty Chemicals Resources |
| SpecialChem |
| Chemical Week |
| ICIS |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.